Novo Nordisk
Novo's Sogroya® receives FDA approval as the first and only once-weekly, long-acting growth hormone for children with Turner Syndrome (TS)
Sogroya® is a once-weekly treatment option for appropriate children 2.5 and older, offering an alternative to once-daily therapy, which may help…
